How dead r we ?!

Quote


Sadly you are as dead as your old technology for HPV testing. Hopefully you have been preparing for this, and have feelers out to jump ship. Good Luck, there is opportunity out there.
 
WHAT ARE YOU TALKING ABOUT?
DIDN'T YOU READ THE NEW GUIDELINES?

We are in great shape. We should be able to close every single one of our docs on cotesting. Unless you are one of those liars who say they've already closed everyone and they are 100% penetrated. You should also be able to steal back any Cervista accounts you lost.

Oh by the way, hybrid capture is newer technology than PCR.
 
Anonymous said:
WHAT ARE YOU TALKING ABOUT?
DIDN'T YOU READ THE NEW GUIDELINES?

We are in great shape. We should be able to close every single one of our docs on cotesting. Unless you are one of those liars who say they've already closed everyone and they are 100% penetrated. You should also be able to steal back any Cervista accounts you lost.

Oh by the way, hybrid capture is newer technology than PCR.
Click to expand...

LOL!!!!
Who needs genotyping anyway?
 
Please quit
If you think that genotyping is that important, you don't understand the algorithm
This was an easy job when we didn't have any competition
Now that there is a little comp, you can't sell your way out of a paper bag.
 
Anonymous said:
Please quit
If you think that genotyping is that important, you don't understand the algorithm
This was an easy job when we didn't have any competition
Now that there is a little comp, you can't sell your way out of a paper bag.
Click to expand...


This poster has not seen the new 2012 ASCCP and USPTF guidelines for Pap smears. Please see the new article in PubMed:

Am J Clin Pathol. 2012 Apr;137(4):516-42.
American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer.

HPV genotyping for 16/18 is indeed a listed option for women between 30 and 65.

Gene-probe, Hologic, and Roche all have new HPV tests. Roche's test is still only FDA approved for prealiquoted ThinPrep specimens, and this will limit sales of their new 4800 platform. The Gene-probe Tigris also does high-volume GC/chlamydia analysis in male and female urine. Digene is not even in the conversation anymore. This older technology has been replaced by more versatile and multfunctional platforms.

The original poster is correct. Digene's Hybrid 2 capture market is essentially dead. I can't imagine why a lab that would buy a new one. Digene sales reps are already out of a job and the more intelligent ones can see the writing on the wall.
 
Drinking the company Kool-aid?
 
Anonymous said:
Right.
You are right there with the docs that genotype all their vaccine patients.
How many genotyping patients will I see in a typical month?

Blood much?
Click to expand...

Genotyping has nothing to do with the vaccine. The reason they genotype is that over 70% of all cervical cx comes from those 2 HR HPV types. Plus, they are the 2 most agressive in terms of infection to CIN3+. Might be time for you to brush up on your training material.
 
Anonymous said:
Genotyping has nothing to do with the vaccine. The reason they genotype is that over 70% of all cervical cx comes from those 2 HR HPV types. Plus, they are the 2 most agressive in terms of infection to CIN3+. Might be time for you to brush up on your training material.
Click to expand...

Perhaps you should brush up on your basic reading comprehension.
I was disparaging the previous post by lumping them into the same class of dolts that
include docs who genotype prior or post vaccine.

Dummy
 


Write your reply...
Top Bottom
Back
Quote